An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development
Introduction: Human immunodeficiency virus (HIV) is a debilitating challenge and concern worldwide. Accessibility to highly active antiretroviral drugs is little or none for developing countries. Production of cost-effective microbicides to prevent the infection with HIV is a requirement. Cyanovirin...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2018-03-01
|
Series: | BioImpacts |
Subjects: | |
Online Access: | https://bi.tbzmed.ac.ir/PDF/bi-8-139.pdf |
id |
doaj-51df670a7206455e8c5edae5a624ffe3 |
---|---|
record_format |
Article |
spelling |
doaj-51df670a7206455e8c5edae5a624ffe32021-06-22T09:21:36ZengTabriz University of Medical SciencesBioImpacts2228-56602228-56522018-03-018213915110.15171/bi.2018.16bi-17489An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical developmentHajie Lotfi0Roghayeh Sheervalilo1Nosratollah Zarghami2Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, IranDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, IranIntroduction: Human immunodeficiency virus (HIV) is a debilitating challenge and concern worldwide. Accessibility to highly active antiretroviral drugs is little or none for developing countries. Production of cost-effective microbicides to prevent the infection with HIV is a requirement. Cyanovirin-N (CVN) is known as a promising cyanobacterial lectin, capable of inhibiting the HIV cell entry in a highly specific manner. Methods: This review article presents an overview of attempts conducted on different expression systems for the recombinant production of CVN. We have also assessed the potential of the final recombinant product, as an effective anti-HIV microbicide, comparing prokaryotic and eukaryotic expression systems. Results: Artificial production of CVN is a challenging task because the desirable anti-HIV activity (CVN-gp120 interaction) depends on the correct formation of disulfide bonds during recombinant production. Thus, inexpensive and functional production of rCVN requires an effective expression system which must be found among the bacteria, yeast, and transgenic plants, for the subsequent satisfying medical application. Moreover, the strong anti-HIV potential of CVN in trace concentrations (micromolar to picomolar) was reported for the in vitro and in vivo tests. Conclusion: To produce pharmaceutically effective CVN, we first need to identify the best expression system, with Escherichia coli, Pichia pastoris, Lactic acid bacteria and transgenic plants being possible candidates. For this reason, heterologous production of this valuable protein is a serious challenge. Since different obstacles influence clinical trials on microbicides in the field of HIV prevention, these items should be considered for evaluating the CVN activity in pre-clinical and clinical studies.https://bi.tbzmed.ac.ir/PDF/bi-8-139.pdfanti-hiv proteinbacteriacyanovirin-nexpression systemtransgenic plantsyeast |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hajie Lotfi Roghayeh Sheervalilo Nosratollah Zarghami |
spellingShingle |
Hajie Lotfi Roghayeh Sheervalilo Nosratollah Zarghami An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development BioImpacts anti-hiv protein bacteria cyanovirin-n expression system transgenic plants yeast |
author_facet |
Hajie Lotfi Roghayeh Sheervalilo Nosratollah Zarghami |
author_sort |
Hajie Lotfi |
title |
An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development |
title_short |
An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development |
title_full |
An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development |
title_fullStr |
An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development |
title_full_unstemmed |
An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development |
title_sort |
update of the recombinant protein expression systems of cyanovirin-n and challenges of preclinical development |
publisher |
Tabriz University of Medical Sciences |
series |
BioImpacts |
issn |
2228-5660 2228-5652 |
publishDate |
2018-03-01 |
description |
Introduction: Human immunodeficiency virus (HIV) is a debilitating challenge and concern worldwide. Accessibility to highly active antiretroviral drugs is little or none for developing countries. Production of cost-effective microbicides to prevent the infection with HIV is a requirement. Cyanovirin-N (CVN) is known as a promising cyanobacterial lectin, capable of inhibiting the HIV cell entry in a highly specific manner. Methods: This review article presents an overview of attempts conducted on different expression systems for the recombinant production of CVN. We have also assessed the potential of the final recombinant product, as an effective anti-HIV microbicide, comparing prokaryotic and eukaryotic expression systems. Results: Artificial production of CVN is a challenging task because the desirable anti-HIV activity (CVN-gp120 interaction) depends on the correct formation of disulfide bonds during recombinant production. Thus, inexpensive and functional production of rCVN requires an effective expression system which must be found among the bacteria, yeast, and transgenic plants, for the subsequent satisfying medical application. Moreover, the strong anti-HIV potential of CVN in trace concentrations (micromolar to picomolar) was reported for the in vitro and in vivo tests. Conclusion: To produce pharmaceutically effective CVN, we first need to identify the best expression system, with Escherichia coli, Pichia pastoris, Lactic acid bacteria and transgenic plants being possible candidates. For this reason, heterologous production of this valuable protein is a serious challenge. Since different obstacles influence clinical trials on microbicides in the field of HIV prevention, these items should be considered for evaluating the CVN activity in pre-clinical and clinical studies. |
topic |
anti-hiv protein bacteria cyanovirin-n expression system transgenic plants yeast |
url |
https://bi.tbzmed.ac.ir/PDF/bi-8-139.pdf |
work_keys_str_mv |
AT hajielotfi anupdateoftherecombinantproteinexpressionsystemsofcyanovirinnandchallengesofpreclinicaldevelopment AT roghayehsheervalilo anupdateoftherecombinantproteinexpressionsystemsofcyanovirinnandchallengesofpreclinicaldevelopment AT nosratollahzarghami anupdateoftherecombinantproteinexpressionsystemsofcyanovirinnandchallengesofpreclinicaldevelopment AT hajielotfi updateoftherecombinantproteinexpressionsystemsofcyanovirinnandchallengesofpreclinicaldevelopment AT roghayehsheervalilo updateoftherecombinantproteinexpressionsystemsofcyanovirinnandchallengesofpreclinicaldevelopment AT nosratollahzarghami updateoftherecombinantproteinexpressionsystemsofcyanovirinnandchallengesofpreclinicaldevelopment |
_version_ |
1721363471308685312 |